Rong Sylvie Yang, Maria Traver, Nathan Barefoot, Tyler Stephens, Casper Alabanza, Javier Manzella-Lapeira, Guozhang Zou, Jeremy Wolff, Yile Li, Melissa Resto, William Shadrick, Yanhong Yang, Vera B Ivleva, Yaroslav Tsybovsky, Kevin Carlton, Joseph Brzostowski, Jason G Gall, Q Paula Lei
Recent work by our laboratory and others indicates that co-display of multiple antigens on protein-based nanoparticles may be key to induce cross-reactive antibodies that provide broad protection against disease. To reach the ultimate goal of a universal vaccine for seasonal influenza, a mosaic influenza nanoparticle vaccine (FluMos-v1) was developed for clinical trial (NCT04896086). FluMos-v1 is unique in that it is designed to co-display four recently circulating haemagglutinin (HA) strains; however, current vaccine analysis techniques are limited to nanoparticle population analysis, thus, are unable to determine the valency of an individual nanoparticle...
February 24, 2024: Scientific Reports